EPCAM and neoplasm: Importantly, in FACS analysis, despite variability in the median fluorescence intensity across the models tested (n = 9), EpCam+ tumor cells homogenously expressed B7H3 (80%–100% cells) at the cell surface, which makes B7H3 an ideal target for ADC based therapy (Figure 1, G and H, and Supplemental Figure 2A).